- Home
- ATOS vs RNAZ Comparison
ATOS vs RNAZ Comparison
Compare ATOS & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | RNAZ |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 27.9M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATOS | RNAZ |
|---|---|---|
| Price | $2.27 | $1.65 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $18.67 | N/A |
| AVG Volume (30 Days) | ★ 47.2K | 46.5K |
| Earning Date | 11-11-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,758.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.58 |
| 52 Week High | $7.56 | $20.99 |
Technical Indicators
Market Signals| Indicator | ATOS | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | N/A |
| Support Level | $2.05 | N/A |
| Resistance Level | $2.60 | N/A |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 39.17 | 0.00 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.